Discontinued — last reported Q4 '17
Tyson Foods Indefinite-Lived Research and Development Assets remained flat by 0.0% to $4.08B in Q3 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $4.08B to $4.08B. Over 4 years (FY 2021 to FY 2025), Indefinite-Lived Research and Development Assets shows relatively stable performance with a 0.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q3 '21 | Q3 '22 | Q3 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|
| Value | $4.08B | $4.08B | $4.08B | $4.08B | $4.08B |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | +0.0% | +0.0% | +0.0% | +0.0% |